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Revisiting Antagonist Effects in
Hypoglossal Nucleus: Brainstem
Circuit for the State-Dependent
Control of Hypoglossal Motoneurons:
A Hypothesis
Victor B. Fenik 1,2*
1 Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA, 2 Websciences
International, Los Angeles, CA, USA
We reassessed and provided new insights into the findings that were obtained in our
previous experiments that employed the injections of combined adrenergic, serotonergic,
GABAergic, and glycinergic antagonists into the hypoglossal nucleus in order to phar-
macologically abolish the depression of hypoglossal nerve activity that occurred during
carbachol-induced rapid-eye-movement (REM) sleep-like state in anesthetized rats. We
concluded that noradrenergic disfacilitation is the major mechanism that is responsible
for approximately 90% of the depression of hypoglossal motoneurons, whereas the
remaining 10% can be explained by serotonergic mechanisms that have net inhibitory
effect on hypoglossal nerve activity during REM sleep-like state. We hypothesized that
both noradrenergic and serotonergic state-dependent mechanisms indirectly control
hypoglossal motoneuron excitability during REM sleep; their activities are integrated and
mediated to hypoglossal motoneurons by reticular formation neurons. In addition, we
proposed a brainstem neural circuit that can explain the new findings.
Keywords: OSA, norepinephrine, serotonin, GABA, glycine, carbachol, REM sleep, motor control
INTRODUCTION
The atonia of skeletal muscles is an insignia that distinguishes rapid-eye-movement (REM) sleep
from the other two states of mammal existence, such as non-REM (NREM) sleep and wakefulness.
It is an important evolutional adaptation that prevents potentially harmful unconsciousness and
uncoordinated motor activity during REM sleep that includes movements of the body and its
extremities, as well as chewing, tongue movements, etc. The importance of the REM sleep muscle
atonia becomes obvious when inadequate muscle paralysis during REM sleep results in the “dream
enactment behavior” in patients with REM sleep behavioral disorder (RBD) (1–3). The RBD is
currently treated with benzodiazepines from which clonazepam is the most effective to reduce the
generation of REM sleep phasic events by enhancing pontine GABA inhibition not affecting the
REM sleep atonia (1, 4, 5).
Pharyngeal muscles also become relaxed during NREM and REM sleep and the sleep-related
reduction of their tonusmay lead to a partial or complete closure of airway in obstructive sleep apnea
(OSA) patients, which have relatively narrow pharyngeal orifice due to anatomical abnormalities
or obesity (6, 7). Another factor that contributes to OSA pathology is the insufficient strength of
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the genioglossus muscles activation in response to negative pres-
sure, which in addition is inhibited during sleep (8, 9). Activ-
ity of the genioglossus and tensor palatine is elevated in OSA
patients compared to healthy controls, which helps to overcome
the anatomical deficiencies and maintain airway opened dur-
ing wakefulness (10). However, these neurological compensatory
mechanisms are eliminated during sleep (10).
Obstructive sleep apnea patients chronically experience repet-
itive nocturnal periods of hypoxia and hypercapnia (11–13).
The obstruction episodes usually end by awakenings that restore
airway patency at the expense of the sleep continuity and the
total sleep (14–16). OSA is a growing sleep disorder (17, 18).
OSApatients suffer from excessive daytime somnolence, impaired
learning and psychomotor vigilance, and overall decrease in qual-
ity of life (16, 19–24). The OSA is also linked to hypertension
(11–13, 24, 25) and an increase of risk for stroke and death
(26). The treatment options for OSA are mostly limited to the
weight loss and use of oral appliances that include the posi-
tive air pressure therapy, surgical procedures, and the electri-
cal stimulation of hypoglossal nerve and upper airway muscles,
whereas no effective pharmacological treatment is available (16,
27–31).
Hypoglossal motoneurons that innervate pharyngeal and
tongue muscles (32) play a key role in the maintenance of
upper airway muscle tone (30). The importance of the activity
of hypoglossal motoneurons for the maintenance of pharyngeal
airway patency is further supported by the findings that an elec-
trical stimulation of hypoglossal nerve during sleep eliminates
hypopnea/apnea events in selected groups of OSA patients (29,
31). Therefore, the emerging understanding of the neurochemical
mechanisms that are responsible for the depression of hypoglossal
motoneuron activity during NREM and REM sleep may provide
valuable information for developing pharmacological treatments
for OSA.
We would like to review and provide new insights into findings
that were obtained in our previous experiments that employed
the injections of the mixtures containing adrenergic, serotoner-
gic, GABAergic, and glycinergic antagonists into the hypoglossal
nucleus in order to pharmacologically abolish the depression of
hypoglossal nerve activity during carbachol-induced REM sleep-
like episodes in anesthetized rats (33–35). In addition, we pro-
pose a hypothetical brainstem neural circuit that can explain the
original data and their new interpretations.
METHODOLOGICAL CONSIDERATIONS
Since effects of the applied antagonists on the activity ofmotoneu-
rons during wakefulness, NREM, and REM sleep are hetero-
geneous and sometimes difficult to interpret, we would like
to theoretically summarize and provide interpretations of the
most common outcomes of antagonist applications on a param-
eter value that is measured during, e.g., sleep and wakefulness
(Figure 1). The parameter is either the amplitude of membrane
potential, or frequency of neuronal firing rate, or amplitude of
moving average of nerve activity, etc. In these theoretical exam-
ples, sleep has a depressant influence on the magnitude of the
measured parameter and, therefore, its value is decreased during
sleep as compared to wakefulness due to either direct inhibition
of motoneurons (Figures 1A–C) or the removal of excitatory
inputs from motoneurons, i.e., disfacilitation (Figures 1D–F).
In addition, applied antagonists may block receptors that are
relevant to the effect of sleep and, thereby, reduce the sleep
effects (Figures 1A,D), or they may block some other recep-
tors that do not mediate the sleep effects but that mediate tonic
FIGURE 1 | Theoretical examples of sleep-induced inhibitory (A–C) and disfacilitatory (D–F) effects on the magnitude of a parameter value measured
during wakefulness (W) and sleep (S) before (baseline W0,S0) and after applications of antagonists (Cases 1 and 2), which supposedly remove either
state-dependent inhibitory (A) and facilitatory (D) inputs, or tonic state-independent inhibitory (B) and facilitatory (E) inputs or simultaneously
state-dependent and state-independent inhibitory (C) and facilitatory (F) inputs. W0 and S0 – the parameter value measured during baseline wakefulness and
sleep, respectively; W1 and S1 – the Case 1 after an antagonist application during wakefulness and sleep, respectively; W2 and S2 – the Case 2 after an antagonist.
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excitatory or inhibitory drives that affect motoneuronal excitabil-
ity (Figures 1B,E).
The Figure 1A demonstrates examples of the parameter value
measured during baseline wakefulness (W) and sleep (S) before
an antagonist application (W0,S0). The Case 1 (W1,S1) shows
an example of a partial removal of sleep-induced direct inhibi-
tion of motoneurons by the antagonist application, i.e., “state-
dependent disinhibition.” Note that the characteristic for the state-
dependent disinhibition is the reduction of the ratio S1/W1 after
antagonists as compared to the baseline ratio S0/W0 by increasing
the parameter value during sleep (S1), whereas its value during
wakefulness (W1) remains similar to the baseline value (W0).
The partial antagonist effects (W1,S1) show inability of an antag-
onist to fully remove the inhibition, which could be explained
by different factors such as contributions of additional inhibitory
neurotransmitters/receptors that are not affected by the applied
antagonist, or incomplete covering of distant receptors due to
insufficient antagonist volume/dose/concentration, or incomplete
antagonism due to insusceptibility of relevant receptors for the
antagonist, etc. By contrast, the full disinhibition (Case 2: W2,S2)
is conclusive, and it can be only interpreted as a complete removal
by an antagonist of the inhibitory input that is solely and fully
responsible for the decrease in the parameter value during sleep
as compared to wakefulness.
The Figure 1B shows two examples (Cases 1 and 2) of the
removal by an antagonist of a tonic not state-dependent inhibition.
The main outcome of such a “state-independent disinhibition”
is the increase in values of a measured parameter during both
wakefulness (W1) and sleep (S1) as compared to its values in the
baseline (W0,S0). In addition, since no state-dependent input is
removed, the ratio S1/W1 is approximately equal to the baseline
ratio S0/W0. The Case W2,S2 shows an example of the removal
of a much stronger tonic inhibitory input so that the parameter
value during sleep S2 become equal to its value during wakeful-
ness in control W0. The ratios of the parameter values after the
antagonist (S1/W1 or S2/W2) could be used to suggest removal of
additional sleep-dependent inhibitory inputs if they significantly
deviate from the baseline ratio S0/W0.
The Figure 1C shows an example of simultaneous removal
by an antagonist of state-dependent and state-independent inhi-
bitions. The similarity of the parameter values after antagonist
during both sleep (S1) and wakefulness (W1) indicates the full
state-dependent disinhibition, whereas the increasing in values
of S1 and W1 relative to the W0 value suggests the additional
removal of state-independent inhibitory inputs.
The Figure 1D demonstrates two cases of the antagonist-
induced reduction of the “state-dependent disfacilitation,” which
occurs when the antagonist removes the same excitatory inputs
that are removed during sleep. In case of the partial antagonist
effect, the decrease in ratio S1/W1 relative to the baseline ratio
S0/W0 is due to the decrease of the parameter value during wake-
fulness (W1), whereas its value during sleep after antagonist (S1)
remains similar to its baseline sleep value (S0). The Case W2,S2
shows a complete state-dependent disfacilitation. In this case, all
state-dependent excitation, which is normally removed by sleep
(S0), is removed by the antagonist and, therefore, the parameter
value W2 is equal to its value during S0. Unlike the partial
antagonism, the complete disfacilitation conclusively suggests that
receptors, which were blocked by the antagonist application, are
fully responsible for the disfacilitatory state-dependent effect of
sleep.
The Figure 1E provides two examples of the removal of a
tonic not state-dependent excitation by an application of an
antagonist. The characteristic feature of this antagonist-induced
“state-independent disfacilitation” is that both parameter values
after antagonist during both wakefulness (W1) and sleep (S1)
decreased as compared to their magnitudes during baseline con-
ditions W0 and S0, respectively. The Case W2,S2 shows an exam-
ple of the removal of a stronger sleep-independent excitation
so that the parameter value W2 is decreased to S0. Also sim-
ilar to the state-independent disinhibition (see Figure 1B), the
state-independent disfacilitation is characterized by both ratios
S1/W1 and S2/W2 being approximately equal to the baseline ratio
S0/W0. Otherwise, a significant difference between these ratios
and the baseline ratio would indicate an additional removal of
state-dependent inputs.
The Figure 1F shows an example of a complete removal of a
state-dependent excitation by an antagonist application, which is
evidenced by S1=W1, and a simultaneous removal of a state-
independent excitation, which reduces both values W1 and S1
below the baseline value S0.
The discussed examples of antagonist modulations of the sleep
effects on a measured parameter provide simplified but useful
interpretations, which may help to uncover underlying mecha-
nisms of the antagonist effects in real antagonist experiments,
e.g., state-dependent or state-independent removal of inhibitory
or excitatory inputs. The important outcome is that during
the antagonist-induced state-dependent disinhibition, the S1/W1
ratio is decreased due to the increase in S1 value, whereas during
state-dependent disfacilitation, the S1/W1 ratio is decreased due
to the decrease in W1 value. Also, only cases with the complete
disinhibition or disfacilitation can be regarded as fully conclusive,
whereas the cases with partial effects could have different inter-
pretations. Naturally, to achieve the complete effects of applied
antagonists, they have to cover and block all receptors thatmediate
a studied function.
REM SLEEP ANIMAL MODELS TO STUDY
NEUROTRANSMITTER MECHANISMS OF
REM SLEEP-RELATED DEPRESSION IN
DIFFERENT POOLS OF MOTONEURONS
Carbachol animal models of REM sleep have been successfully
used for decades to study mechanisms of both REM sleep gen-
eration and REM sleep-related muscle atonia, in conjunction with
the naturally sleeping behaving animals [reviewed by Kubin (36)].
Carbachol, a dual muscarinic and nicotinic cholinergic agonist,
injected into dorsolateral pontine tegmenum in cats or into the
homologous region in rats (the sub-Locus Coeruleus region or the
sub-laterodorsal nucleus) mimics the increased cholinergic drive
in these regions during natural REM sleep and, therefore, elicits
REM sleep-like state (REMSLS) in decerebrated or anesthetized
animals. The REMSLS have many features of natural REM sleep,
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including atonia of postural and orofacial muscles, which make
these model useful to study neurochemical mechanisms of the
muscle atonia. The REMSLS may also be triggered by pontine
injection of bicuculline, a GABAA receptor antagonist (37, 38), or
by pontine electrical stimulation (39).When anesthetized animals
are used to produce REMSLS, there is always a concern that anes-
thetic may affect the experimental outcomes. However, the out-
standing stability and repeatability of anesthetized preparations,
which allows performing complex in vivo experiments with pre-
cise temporal dissection of investigated phenomena under highly
controlled conditions, make their use often more advantageous
over behaving animals. Obviously, important findings and con-
clusions obtained in anesthetized animals have to be confirmed in
behaving animals.
THE NEUROTRANSMITTER MECHANISMS
OF REM SLEEP-RELATED DEPRESSION
OF SPINAL, TRIGEMINAL, AND
HYPOGLOSSAL MOTONEURONS
Spinal Motoneurons
Theneurotransmitters that are involved in theREMsleep-induced
muscle atonia were first conclusively demonstrated in the pio-
neering work conducted in Michael Chase’s laboratory (40). By
employing the intracellular recording from lumbar motoneurons
in behaving cats, authors determined that the REM sleep-induced
atonia of skeletal muscles is due to postsynaptic inhibition of
spinal motoneurons mediated by glycine. Indeed, iontophoreti-
cally applied strychnine, a glycinergic antagonist, abolished all
important REM sleep-induced features that contribute to the
motoneuron deactivation during REM sleep: (1) hyperpolariza-
tion of the motoneuron membrane that increases the threshold
for the action potential generation; (2) decrease in input resistance
that shunted summation of sub-threshold excitatory postsynaptic
potentials; and (3) the increase in rheobase that is a principal
measure of neuronal excitability. Since both membrane hyper-
polarization and increase in membrane conductance contribute
to increase in rheobase, the abolition of the REM sleep-related
increase in rheobase by strychnine is the major finding obtained
in this study indicating that the reduction of excitability of lum-
bar motoneurons is due to postsynaptic inhibition mediated by
glycine. In addition, relatively large spontaneous sub-threshold
inhibitory postsynaptic potentials (IPSPs) were observed during
NREM and with fourfold higher frequency during REM, sleep
(40). The amplitude and frequency of these IPSPs were signifi-
cantly reduced by strychnine during both NREM and REM sleep
suggesting their glycinergic nature (40, 41). However, the causal
relationship was not demonstrated between the appearance of the
IPSPs and the decrease inmotoneuron excitability in these studies.
In addition during carbachol-induced REMSLS, the appearance
of the IPSPs did not cause a significant membrane hyperpolar-
ization in either spinal (42) or hypoglossal motoneurons (43).
Furthermore, it has been reported that the IPSPs are closely
associated with ponto-geniculo-occipital (PGO) waves (44, 45),
which are regarded as the “phasic” REM sleep events that have
different generation mechanisms compared to the “tonic” REM
sleep events, such as muscle atonia (46). For example, the occur-
rence of PGO waves did not correlate with the loss of muscle
atonia produced by the lesions of the dorsal pontine tegmentum
in cats (47).
Trigeminal Motoneurons
Similar IPSPs were found during intracellular recordings in
trigeminalmotoneurons duringREMsleep (48). These IPSPswere
also strychnine sensitive and their appearance strongly correlated
with PGO waves (49, 50). However, in recent studies, antago-
nizing of glycine and GABAA receptors in the motor trigeminal
nucleus did not abolish REM sleep-related depression of mas-
seter muscle EMG in behaving rats (51, 52). Likewise after the
combined antagonism of GABAA, GABAB, and glycine receptor
in the motor trigeminal nucleus, the relative REM sleep-induced
depression of trigeminal motoneurons remained similar to that
before antagonists, even though the antagonists increased the
masseter muscle activity during REM sleep to the level that was
observed during NREM sleep before the antagonists (53). On
the other hand, there is convincing evidence that withdrawal of
glutamate excitation is responsible for depression of trigeminal
motoneurons during NREM sleep relative to wakefulness, but not
during REM sleep (54). Also, the interaction between noradren-
ergic and glutamatergic signaling has been recently described at
the trigeminal motor nucleus (55). Thus, neurotransmitter mech-
anisms of REM sleep-induced depression of trigeminal motoneu-
rons remain uncertain.
REM Sleep-Induced Hypoglossal
Motoneuron Depression
The mechanisms of REM sleep-induced hypoglossal motoneuron
depression (REM-HD) were studied using intracellular recording
during carbachol-induced REMSLS in anesthetized and decer-
ebrated cats (43). The main finding of this study was that
the rheobase of hypoglossal motoneurons significantly increased
by 60% during REMSLS. Also, similar to spinal and trigem-
inal motoneurons, large strychnine-sensitive IPSPs appeared
in hypoglossal motoneurons during REMSLS. Based on this
similarity and indications that they are strychnine sensitive,
authors concluded that postsynaptic inhibition was responsi-
ble for the decrease in hypoglossal motoneuron excitability
during REMSLS. However, statistical analyses were not pro-
vided for the strychnine sensitivity of these IPSPs. Also sur-
prisingly, effects of strychnine on the magnitude of rheobase
were not described, which would provide direct evidence that
glycinergic inhibition causes the reduction of motoneuron
excitability (43).
Additional analyses of changes in motoneuron electrophysi-
ological properties (56) and in field potentials evoked by stim-
ulation of ipsilateral hypoglossal nerve (57) were reported in
subsequent studies of hypoglossalmotoneurons during carbachol-
induced REMSLS. However, strychnine was not used in those
studies to confirm the glycinergic nature of the observed phenom-
ena. Also, the behavior of the IPSPs and rheobase in hypoglossal
motoneurons was described during natural sleep and wakeful-
ness, although no antagonist was used in that study to prove
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the inhibitory effects (58). Thus, the hypothesis regarding the
key role of glycinergic inhibition in REM-HD is only based on
observations that glycinergic IPSPs appear during both natural
REM sleep and carbachol-induced REMSLS. The assumption that
they lead to the decrease of excitability of hypoglossal motoneu-
rons during REM-HD was not experimentally tested. Also, no
attempts were made to verify if the decrease of excitability of
hypoglossal motoneurons during REM-HD was strychnine sen-
sitive (e.g., increase in rheobase, membrane hyperpolarization,
or decrease in membrane resistance). In addition, “extracellular”
studies, in which the activity in hypoglossal nerve or genioglossal
muscle wasmeasured, did not provide evidence regarding a role of
glycine in REM-HD during carbachol-induced REMSLS in either
decerebrated cats (59) or anesthetized rats (33, 34). Furthermore,
no contribution of either GABA or glycine was found to REM-HD
in behaving rats (60).
The more conclusive results regarding neurotransmitter con-
trol of excitability of hypoglossal motoneurons during REM-HD
were obtained using carbachol model of REM sleep in anes-
thetized rats. The antagonism of noradrenergic and serotoner-
gic receptors within and around hypoglossal nucleus abolished
REM-HD that occurred during carbachol-induced REMSLS in
anesthetized rats (35). These findings provide a strong support
for the hypothesis that aminergic disfacilitation plays a key role
in REM-HD. Quantitatively, contribution of noradrenaline to
REM-HD was much stronger compared to 5HT. Importantly,
the significant involvement of noradrenaline in REM-HD was
experimentally demonstrated in behaving rats (61). Since the
serotonin contribution to REM-HD was relatively small (35),
it was not observed in behaving rats (62) probably due to the
inheritably higher variability of results obtained in behaving
animals.
Other neurotransmitters, such as glutamate (63, 64), presy-
naptically acting acetylcholine (63), and GABA (65), have been
implicated in the mechanisms of REM-HD. Recently, a relatively
strong effect of the antagonism of muscarinic receptors within
hypoglossal nucleus on the genoiglossusmuscle activitywas found
during wakefulness, NREM sleep, and REM sleep in behaving rats
(66). The effectiveness of this antagonism was more pronounced
during REM sleep, which suggested that postsynaptic cholinergic
inhibition may also contribute to REM-HD (66).
Conclusion
Thus, to date, the abolition of REM sleep-related depression of
motoneurons, which is achieved by application of antagonists and
can be regarded as the “gold standard” to define the responsi-
ble neurotransmitters, has been demonstrated for two pools of
motoneurons – spinal and hypoglossal. First of all, this indicates
that different neurotransmitters mediate REM-induced depres-
sion of muscle tone in different motoneurons. Second, those stud-
ies conclusively showed that (1) REM sleep-induced depression
of spinal motoneurons is due to postsynaptic inhibition medi-
ated by glycine (40) and (2) REM sleep-induced depression of
hypoglossal motoneurons is due to withdrawal of noradrenergic
and serotonergic drives (35). The latter has been determined
during REMSLS in anesthetized animals (35) and confirmed in
behaving animals (61).
REVISITING ANTAGONIST EFFECTS ON
HYPOGLOSSAL NERVE ACTIVITY DURING
CARBACHOL-INDUCED REMSLS IN
ANESTHETIZED RATS
We have conducted a series of experiments with a goal to
determine the neurochemical mechanisms of the depression of
hypoglossal motoneurons during REMSLS using a carbachol
model of REM sleep in anesthetized rats (33–35). The REMSLS
were triggered by injections of carbachol into pontine dorsal sub-
coeruleus region (or sub-laterodorsal nucleus) (38). The carbachol
injections repeatedly elicited many features of natural REM sleep
that included activation of EEG (appearance of the high frequency
in 6–12Hz band without a decrease in EEG amplitude), hip-
pocampal theta rhythm, depression of hypoglossal nerve activity,
and silencing of LC and A5 neurons (36, 67, 68). Only some
features of natural REM sleep (the desynchronization of EEG and
the REM sleep phasic events with the increased respiratory rate)
were not observed during REMSLS in this model due to anes-
thesia. However, the high stability of this preparation and excel-
lent repeatability of the magnitude of the decrease in inspiratory
hypoglossal nerve activity during REMSLS, which is analogous to
REM-HD, allowed us to test effects of various antagonists on the
REM-HD. Antagonists were injected into ipsilateral hypoglossal
nucleus by three 40 nL injections that were evenly placed along the
hypoglossal nucleus to ensure that all hypoglossal motoneurons
are covered with antagonists right after the end of the injections.
The Figure 2 summarizes the effects of antagonists on the
REM-HD that were obtained in our series of experiments (33–35).
The amplitudes of moving average of hypoglossal nerve activity
were measured before (B) and during carbachol (C) at baseline
(B0,C0), right after (B1,C1) and at approximately 1 h after (B2,C2),
the antagonist injections into hypoglossal nucleus. Additional
episodes of REMSLS were elicited by carbachol at later times to
observe the recovery process (not shown).
The Figure 2A shows the results of injections of the antag-
onist mixture that contained the solution of the following four
antagonists in saline: 1mM of strychnine, a glycinergic receptor
antagonist; 1mM of bicuculline, a GABAA receptor antagonist;
0.2mM of prazosine, an α1-adrenoceptor antagonist; and 1mM
of methysergide, a broad-spectrum serotonergic (5HT) receptor
antagonist (33). The effectiveness of each antagonist in the mix-
ture was verified in separated experiments. The injections of the
antagonist mix into hypoglossal nucleus resulted in immediate
increase of hypoglossal nerve activity due to blockade of glycine
and GABAA receptors (see B1 in Figure 2A). We expected that
after the blockade of the four types of receptors, which were
implicated in the mediation of REM-HD and targeted by the
antagonist mix, the REM-HDwould be abolished during the early
REMSLS (B1,C1). However, the REM-HD was still very promi-
nent and the ratio of the amplitudes of the nerve activity before
and during carbachol in the early REMSLS was C1/B1= 27%,
similar to baseline C0/B0= 18%. The failure of the antagonist
mix to abolish the REM-HD early after the antagonists cannot
be explained by partial covering of the relevant receptors because
we specifically calculated the number, placement, and volume
of the injections to be able to cover all motoneurons by the
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FIGURE 2 | Summary of hypoglossal nerve activity during carbachol-
induced REM sleep-like episodes that were evoked before (baseline
B0,C0) and at different times after (B1,C1 and B2,C2), the injections of
the antagonist combinations into hypoglossal nucleus. (A) Combined
injections of prazosin, methysergide, bicuculline and strychnine. (B) Combined
injections of prazosin, methysergide and bicuculline. (C) Combined injections
of prazosin and methysergide. (D) Injections of prazosin only. (E) Injections of
methysergide only. Pz, prazosin, an α1-adrenoceptor antagonist; Me,
methysergide, a broad-spectrum serotonergic antagonist; Bi, bicuculline, a
GABAA antagonist; Str, strychnine, a glycinergic antagonist. B0 and C0,
baseline hypoglossal nerve activity measured before and during carbachol,
respectively; B1 and C1, hypoglossal nerve activity during “early” carbachol
responses; B2 and C2, hypoglossal nerve activity during “late” carbachol
responses. *p<0.05, paired t-test [adapted from Fenik et al. (33–35)].
antagonists immediately after the end of the antagonist injections.
In addition, according to the analysis of the diffusion of the
antagonists from their injection sites, the effective diameter of the
antagonist injections after 10min following their injection (the
injection time 8.2min plus the time when the measurements B1
and C1 were taken 1.2–2.9min after the end of the injections)
would be approximately twice larger than the diameter of the
hypoglossal nucleus (34). Furthermore, our previous experience
with injections of similar concentrations of glycine, GABAA, α1-
adrenoceptor or 5HT receptor agonists, and antagonists into the
hypoglossal nucleus in the same preparations, suggested that
antagonists blocked the effects of either endogenous or exoge-
nous ligands within 1min after injections. Therefore, the failure
of the antagonist mix to abolish the REM-HD early after the
antagonists cannot be explained by insufficient timing that may
be required to block the relevant receptors within the hypoglossal
nucleus.
Thus, the receptors that were blocked by themixture of the four
antagonists within the hypoglossal nucleus are not responsible
for the REM-HD. Similar conclusions regarding the involvement
of glycinergic, GABAergic, and 5HT receptors in REM-HD were
made in behaving rats (60, 62). In addition according to our previ-
ous experience, the removing of endogenous adrenergic excitation
by prazosin injections into hypoglossal nucleus did not reduce the
spontaneous activity in hypoglossal nerve activity in anesthetized
rats (69). Likewise, blocking 5HT receptors by iontophoretically
applied methysergide did not change the spontaneous firing rate
of extracellularly recorded hypoglossal motoneurons in decere-
brate cats (70). Thus, the spontaneous excitatory noradrenergic
and 5HT drives within the hypoglossal nuclei are negligible and,
therefore, their withdrawal during REM sleep-like effects cannot
explain the REM-HD in these preparations.
However, when carbachol was injected at 27–83min after the
end of the antagonist injections (Figure 2A, B2,C2), the REM-HD
was abolished. Interestingly, an additional excitatory component
appeared in hypoglossal nerve activity after carbachol injection
C2. We explained the abolition of the REM-HD during the late
carbachol injections B2,C2 by the diffusion of the antagonists out-
side the hypoglossal nucleus and blocking the relevant receptors
within the reticular formation (34).
The behavior of the antagonist mix without strychnine
(Figure 2B) was very similar to the full mixture, suggesting that
the antagonism of glycine receptors did not play a role in the
abolition of REM-HD during the late carbachol injections. The
small excitation was also present during late carbachol injections
(Figure 2B, C2). When these trials and the trials with the full
antagonist mixture are combined, the increase in hypoglossal
nerve activity during carbachol C2 (Figures 2A,B) became sta-
tistically different from the nerve activity before carbachol B2
(p< 0.05; n= 12; paired Student’s t-test).
When only two antagonists, such as prazosin andmethysergide,
were left in the mixture, the REM-HD was still abolished at the
late carbachol injections (Figure 2C, B2,C2). Since the trials with
prazosin or methysergide alone failed to abolish the REM-HD
(Figures 2D,E), the antagonism of α1-adrenoceptors and 5HT
receptors is necessary and sufficient to abolish the REM-HD in
this preparation. In these trials during late carbachol injections
(B2,C2), there was no excitatory component, which suggests that
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the blocking of GABAA receptors was responsible for its appear-
ance when bicuculline was present in the antagonist mix.
The abolition of the REM-HD by the mix containing only
prazosin and methysergide is a typical example of the complete
disfacilitation (see Figure 1D, W2,S2). One conclusion could
be made that prazosin removed some adrenergic REM sleep-
dependent excitatory input to hypoglossal motoneurons, whereas
methysergide removed the remaining REM sleep-dependent exci-
tation mediated by serotonin. Therefore, in order to quantify
the contribution of each adrenergic and 5HT contribution to
the state-dependent excitation of hypoglossal motoneurons, we
conducted two separated trials with injections of prazosin alone
and methysergide alone into hypoglossal nucleus.
Unexpectedly, the “prazosin only” injections reduced the level
of spontaneous activity in hypoglossal nerve B2 at the time of
the late carbachol-inducedREMSLS (Figure 2D) approximately to
the level of the nerve activity during baseline carbachol responses
C0. Thus, all excitatory inputs to hypoglossal motoneurons, the
removal of which was necessary for the full disfacilitation, were
removed by prazosin alone. However, a small but statistically
significant [p< 0.05, n= 6 (35)] depression of hypoglossal nerve
activity was still present during the late carbachol responses
(B2,C2) and the level C2 decreased below the level C0 of the
nerve activity. Thus, when methysergide was present in the mix
with prazosin, it increased level C2 to the level B2. Such an
effect of methysergide is in accordance with the removal of state-
dependent inhibitory inputs to hypoglossal motoneurons, similar
to the cases of disinhibition in Figure 1A.
From the trials with prazosin only injections, it is possible
to quantitatively estimate the relative contributions of the
noradrenergic and serotonergic mechanisms to REM-HD.
Prazosin decreased spontaneous activity in hypoglossal
nerve from B0= 100% to B2= 20.8% (Figure 2D). During
the following carbachol, the nerve activity decreased to
C2= 14.8% of baseline (35). Thus, we can calculate the total
magnitude of the nerve depression: 100–14.8= 85.2(%);
a noradrenergic contribution: 100–20.8= 79.2(%); and a
serotonergic contribution: 20.8–14.8= 6(%). Thus, the estimated
relative contribution of noradrenergicmechanisms to REM-HD is
79.2/85.2 100= 93(%), and the estimated relative contribution
of serotonergic mechanisms is 6/85.2 100= 7(%).
The “methysergide only” injections had mixed effects on the
activity in hypoglossal nerve (Figure 2E) that can be explained
by effects of methysergide on multiple receptors (71). During the
time of the late carbachol-induced REMSLS, spontaneous nerve
activity B2 tended to decrease below level B0. This decrease might
indicate a net state-dependent disfacilitatory effect of methy-
sergide on REM-HD. However, the facts that prazosin alone fully
disfacilitated hypoglossal nerve activity (evidenced by B2=C0 in
Figure 2D) implies that it was rather a removal of REM state-
independent inputs. In addition, the level of the nerve activity
during the late REMSLS (C2 in Figure 2E) tended to be higher
than that during the baseline REMSLS (C0), which suggests that
methysergide removed some inhibitory inputs to hypoglossal
motoneurons (see Figure 1A, Case 2). This disinhibitory effect
of methysergide was relatively small but the value C2 was likely
to be reduced by the state-independent disfacilitation (see above
and Figure 1E).
Thus, it seems that prazosin is fully responsible for the disfa-
cilitation, whereas methysergide for the disinhibitory effects on
the REM-HD. The inhibitory role of 5HT in REM-HD is unex-
pected. However, this conclusion is additionally supported by
the time-courses of the effects methysergide on the spontaneous
activity in the hypoglossal nerve (Figure 3). During the diffusion,
prazosin blocked more α1-adrenoceptors and more excitatory
inputs to hypoglossal motoneurons were removed, which pushed
FIGURE 3 | The time-courses of spontaneous activity recorded in the hypoglossal nerve after injections of a mix containing both prazosin (Pz) and
methysergide (Me) (open squares), prazosin only (filled circles) and methysergide only (filled triangles) into hypoglossal nucleus. Modified from Fenik
et al. (35) with permission of the American Thoracic Society. Copyright © 2015 American Thoracic Society.
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the hypoglossal nerve activity down to its minimal level approx-
imately at the time of the late carbachol responses (Figure 3,
filled circles). The methysergide had less dramatic effects on the
spontaneous nerve activity (Figure 3, filled triangles) that affected
the time-course of combined antagonist effects (open squares).
In addition, the time-course of methysergide effects had a bi-
phasic shape. Initially, the spontaneous activity in hypoglossal
nerve decreased likely due to the state-independent disfacilita-
tion (see above), i.e., affecting receptors that likely do not con-
tribute to REM-HD. However, at later times, hypoglossal nerve
activity started to increase and reached its peak approximately
at the time of the late carbachol responses (see Figure 3). This
increase of hypoglossal nerve activity suggests that methysergide
diffused to locations where it affected different 5HT receptors,
so that its net effect was disinhibitory to hypoglossal motoneu-
rons. We believe that these are the 5HT receptors, which medi-
ate the depression of hypoglossal nerve activity in the “prazosin
only” trials during the late carbachol-induced REMSLS (C2 in
Figure 2D).
In summary, the disfacilitation of noradrenergic drive is
a major mechanism of the REM-HD that is responsible for
approximately 90% of REM-HD. The significant involvement of
noradrenaline in REM-HD is also supported by experiments in
behaving rats (61). The 5HT-related inhibition of hypoglossal
motoneurons additionally contributes to approximately 10% of
REM-HD. Possibly because of its relatively small magnitude and
the inheritably larger data variability in behaving animals, the
contribution of 5HT was not detected in behaving rats (62).
THE NEURAL CIRCUIT OF
STATE-DEPENDENT CONTROL OF
HYPOGLOSSAL MOTONEURONS
We would like to suggest a brainstem neural circuit that can
explain the state-dependent control of hypoglossal motoneurons.
It contains the minimal number of neuronal pools that are nec-
essary and sufficient to fulfill our conclusions: (1) neither glycine
norGABAA receptors that are locatedwithin or near the hypoglos-
sal nucleus are responsible for REM-HD, at least in this animal
model of REM sleep; (2) there is, however, a small GABAA-
dependent excitation of hypoglossal motoneurons during REM-
HD; (3) blocking both α1-adrenergic and 5HT receptors outside
the hypoglossal nucleus is necessary for the abolition of REM-HD;
(4) the major mechanism of REM-HD is a noradrenergic disfa-
cilitation of hypoglossal motoneurons; and (5) 5HT mechanisms
contribute to REM-HD by net inhibitory effects on hypoglossal
motoneurons.
The Figure 4 shows the suggested neural circuit. The major
neuronal pools that are responsible for the state-dependent con-
trol of hypoglossal motoneurons are noradrenergic A7 neurons
and hypothetical medullary reticular formation neurons (RF-
neurons) that mediate the noradrenergic excitatory drive from
A7 neurons to hypoglossal motoneurons (72). We propose that
the A7 neurons excite the RF-neurons by activating their α1-
adrenoceptors, which are located within the radius of the dif-
fusion of the antagonists (see Figure 4) that was estimated
0.9–1.4mm from the center of the hypoglossal nucleus (34).
FIGURE 4 | A hypothetical brainstem circuit that illustrates the key neuronal pools, which participate in the state-dependent control of hypoglossal
motoneuron excitability during REM sleep. The reticular formation neurons (RF-neurons) integrate and mediate noradrenergic and serotonergic drives to
hypoglossal motoneurons. The REM-OFF A7 noradrenergic neurons excite RF-neurons via α1-adrenoceptors. The RF-neurons are tonically inhibited by local
GABAergic neurons, activity of which is controlled by REM-OFF raphe serotonergic neurons via inhibitory 5HT1 receptors. The mediators and receptors through
which RF-neurons directly or indirectly excite hypoglossal motoneurons remain to be determined. A hypothetical REM-ON excitatory drives to hypoglossal and/or
RF-neurons are controlled by GABAA inhibitory receptors. The curved line shows the extent of the diffusion of antagonists that were injected into hypoglossal nucleus
as discussed in this review.
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These RF-neurons have a net excitatory effect on hypoglossal
motoneurons, but their projections to hypoglossal motoneurons
(direct or indirect) and the involved neurotransmitters/receptors
need to be determined in future experiments. The A7 neurons
decrease their activity during REMSLS (73) and are likely to be
silent during REM sleep (74). Therefore, the silencing of A7 neu-
rons during REM sleep disfacilitates the RF-neurons and, thereby,
hypoglossal motoneurons. Our hypothesis that aminergic drive
affects hypoglossal motoneurons indirectly, i.e., mediated by RF-
neurons, is in accordance with intracellular studies, in which no
evidence for aminergic disfacilitation was found in hypoglossal
motoneurons during REM sleep or REMSLS (56, 58).
To explain mechanisms of both the disinhibitory effect of
methysergide on REM-HD and the resultant net inhibitory effect
of 5HT neurons on hypoglossal motoneurons during REM sleep,
we hypothesize that 5HT neurons, which are located in medullary
and/or pontine raphe nuclei, inhibit local GABAergic neurons via
5HT1A receptors. These GABAergic neurons, in turn, inhibit the
RF-neurons (see Figure 4). Since brainstem 5HT raphe neurons
are REM-OFF neurons (75, 76), they inhibit the local GABAergic
neurons during wakefulness and NREM sleep. Both the low activ-
ity of the GABAergic neurons and a high level of noradrenergic
excitatory drive from A7 neurons maintain the activity of the RF-
neurons and, in turn, hypoglossal motoneurons during wakeful-
ness and NREM sleep. During REM sleep, raphe neurons become
silent and, therefore, disinhibit the GABAergic neurons, which, in
turn, increase inhibition of the RF-neurons. The increased inhibi-
tion of the RF-neurons and, at the same time, their disfacilitation
due to silencing of A7 neurons result in the depression of both the
RF-neuron activity and hypoglossal motoneurons, during REM
sleep.
We also hypothesize that the mechanism of methysergide
effects on REM-HD and the spontaneous activity in hypoglossal
nerve in our antagonist experiments can be explained by the
ability of methysergide to activate 5HT1A receptors (77). Con-
sequently, methysergide diffused in the reticular formation and
inhibited the local GABAergic neurons by activating their 5HT1A
receptors; this disinhibited the RF-neurons and, in turn, hypoglos-
sal motoneurons (see the time-course of methysergide effects in
Figure 3). The disinhibitory effect of methysergide on REM-HD
can be explained by the following mechanism: after methysergide
binds and activates 5HT1A receptors on the local GABAergic
neurons, the silencing of raphe neurons during REMSLS cannot
disinhibit these GABAergic neurons because their inhibition is
maintained by methysergide, thereby blocking the net inhibitory
effect of 5HT on hypoglossal motoneurons during REM-HD.
The hypothesized presence of 5HT1A receptors on the local
GABAergic neurons allows us to minimize the number of
neuronal pools in the proposed circuit. In addition, this hypoth-
esis is supported by the experimental observation that the sys-
temically applied low doses of 8-OH-DPAT, a specific 5HT1A
receptor agonist, readily silenced 5HT raphe neurons but do not
affect the activity in hypoglossal nerve (78). Our explanation is
that the 8-OH-DPAT inhibits the activity of 5HT raphe neurons
via their own 5HT1A receptors. However, at the same time, the 8-
OH-DPAT also occupies and activates the 5HT1A receptors that
are located on the local GABAergic neurons (see Figure 4). The
continuing activation of the GABAergic 5HT1A receptors keeps
them inhibited despite the reduction of the 5HT drive from the
silenced raphe neurons. Therefore, no change in the activity of
hypoglossal nerve is observed.
To explain the excitatory effects of REM sleep on hypoglossal
nerve activity, which was unmasked by bicuculline when it was
present in the antagonist mix in our experiments, a hypotheti-
cal REM-ON excitatory drive has been added to the proposed
circuit (see Figure 4). This excitatory drive activates hypoglossal
motoneurons either directly or through the RF-neurons and it is
controlled by GABAergic inhibition via GABAA receptors that
were blocked by bicuculline.
CONCLUSION
The presented hypothetical neuronal circuit synthetizes and
explains many experimental observations that were obtained up
to date. The important new hypotheses that are introduced in
this manuscript are the following: (1) the state-dependent control
of hypoglossal motoneuron excitability is mediated by the RF-
neurons that integrate the noradrenergic and serotonergic drives;
(2) the noradrenergic disfacilitation during REM sleep is the
key mechanism that is responsible for REM-HD; and (3) the
serotonergic mechanisms involve local GABAergic neurons and
contribute to REM-HD by a net inhibitory effect on the excitabil-
ity of hypoglossal motoneurons. We believe that the outlined
hypotheses and the proposed neuronal circuit will direct future
experiments to advance our understanding of neurochemical
mechanisms of REM-HD.
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